SCHEMBL3531650

SCHEMBL3531650

O=C1CCCNc2cc(Cl)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
F7 P08709 1/20 0.44
PARP1 P09874 1/20 0.44
F3 P13726 1/20 0.44
PARP10 Q53GL7 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP1 P29466 1/20 0.44
MPI P34949 1/20 0.44
HTT P42858 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051842 1.00 GAA (0.44) GAAMEN1KMT2ALMNAF7
SCHEMBL6256563 0.89 MEN1 (0.54) GAAMEN1KMT2ALMNAF7
SCHEMBL533885 0.86 MEN1 (0.47) GAAMEN1KMT2ALMNAF7
SCHEMBL29721553 0.86 MEN1 (0.47) GAAMEN1KMT2ALMNAF7
SCHEMBL9822340 0.81 SRD5A1 (0.51) MEN1KMT2ALMNAF7PARP1
SCHEMBL3532979 0.79 PARP10 (0.47) GAAMEN1KMT2ALMNAPARP1
SCHEMBL31239363 0.78 CES1 (0.48) GAAMEN1KMT2AF7PARP1
SCHEMBL23160447 0.76 PARP10 (0.60) F7PARP1F3PARP10PPOX
SCHEMBL6409810 0.76 HTT (0.48) GAAMEN1KMT2ALMNAPARP1
SCHEMBL15415006 0.76 MEN1 (0.63) GAAMEN1KMT2ALMNAPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) 2023-05-25 US disclosed
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) 2023-05-25 US disclosed
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) 2023-05-25 US disclosed
EP-4137483-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Zhongze Therapeutics, Co. Ltd. (CN) 2023-02-22 EP disclosed
EP-4137483-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Zhongze Therapeutics, Co. Ltd. (CN) 2023-02-22 EP disclosed
CN-113527206-B Benzoazaheterocycle compound, preparation method and application thereof 上海中泽医药科技有限公司 2022-12-30 CN disclosed
CN-113527206-A Benzoazaheterocycle compound, preparation method and application thereof 上海中泽医药科技有限公司 2021-10-22 CN disclosed
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-20190125825-A1 SMALL-MOLECULE ADJUVANTS FOR ANTIBIOTICS TO ADDRESS ANTIBIOTIC RESISTANCE HIGH POINT UNIVERSITY 2019-05-02 US disclosed
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed
US-7749992-B2 Compounds and methods for treating dislipidemia ELI LILLY AND COMPANY (US) 2010-07-06 US disclosed
EP-1670768-B1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2009-09-09 EP disclosed
EP-2098512-A1 Compounds and methods for treating dyslipidemia Eli Lilly & Company (US) 2009-09-09 EP disclosed
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia ELI LILLY AND COMPANY (US) 2007-11-01 US disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125825-A1 SMALL-MOLECULE ADJUVANTS FOR ANTIBIOTICS TO ADDRESS ANTIBIOTIC RESISTANCE MYD88, TLR5, TLR3 GAA 3627/4885MEN1 3670/4885KMT2A 1854/4885
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF HDAC11, HDAC1, HDAC6 GAA 672/4885MEN1 1965/4885KMT2A 130/4885
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 GAA 602/4885MEN1 2857/4885KMT2A 2100/4885
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP GAA 91/4885MEN1 4630/4885KMT2A 4450/4885
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia APOB, CETP, PCSK9 GAA 445/4885MEN1 1183/4885KMT2A 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.